Cullinan Therapeutics Inc (CGEM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 95.66 is considered Overvalued compared with the five-year average of -5.92. The fair price of Cullinan Therapeutics Inc (CGEM) is between 8.32 to 12.44 according to relative valuation method. Compared to the current price of 16.16 USD , Cullinan Therapeutics Inc By Overvalued By 29.94%.

Relative Value

Fair Zone

8.32-12.44

Current Price：16.16

29.94%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Cullinan Therapeutics Inc (CGEM) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Cullinan Therapeutics Inc (CGEM) has a current Price-to-Book (P/B) ratio of 1.32. Compared to its 3-year average P/B ratio of 1.17, the current P/B ratio is approximately 13.69% higher. Relative to its 5-year average P/B ratio of 1.35, the current P/B ratio is about -1.68% higher. Cullinan Therapeutics Inc (CGEM) has a Forward Free Cash Flow (FCF) yield of approximately -29.16%. Compared to its 3-year average FCF yield of -27.78%, the current FCF yield is approximately 4.96% lower. Relative to its 5-year average FCF yield of -20.46%, the current FCF yield is about 42.53% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CGEM competitors is 20.93, providing a benchmark for relative valuation. Cullinan Therapeutics Inc Corp (CGEM.O) exhibits a P/S ratio of 95.66, which is 357% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CGEM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CGEM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CGEM currently overvalued or undervalued?

Cullinan Therapeutics Inc (CGEM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 95.66 is considered Overvalued compared with the five-year average of -5.92. The fair price of Cullinan Therapeutics Inc (CGEM) is between 8.32 to 12.44 according to relative valuation method. Compared to the current price of 16.16 USD, Cullinan Therapeutics Inc is Overvalued By 29.94%.

What is Cullinan Therapeutics Inc (CGEM) fair value?

CGEM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cullinan Therapeutics Inc (CGEM) is between 8.32 to 12.44 according to relative valuation method.

How does CGEM's valuation metrics compare to the industry average?

The average P/S ratio for CGEM's competitors is 20.93, providing a benchmark for relative valuation. Cullinan Therapeutics Inc Corp (CGEM) exhibits a P/S ratio of 95.66, which is 357.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Cullinan Therapeutics Inc (CGEM) as of Mar 02 2026?

As of Mar 02 2026, Cullinan Therapeutics Inc (CGEM) has a P/B ratio of 1.32. This indicates that the market values CGEM at 1.32 times its book value.

What is the current FCF Yield for Cullinan Therapeutics Inc (CGEM) as of Mar 02 2026?

As of Mar 02 2026, Cullinan Therapeutics Inc (CGEM) has a FCF Yield of -29.16%. This means that for every dollar of Cullinan Therapeutics Inc's market capitalization, the company generates -29.16 cents in free cash flow.

What is the current Forward P/E ratio for Cullinan Therapeutics Inc (CGEM) as of Mar 02 2026?

As of Mar 02 2026, Cullinan Therapeutics Inc (CGEM) has a Forward P/E ratio of -3.14. This means the market is willing to pay $-3.14 for every dollar of Cullinan Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cullinan Therapeutics Inc (CGEM) as of Mar 02 2026?

As of Mar 02 2026, Cullinan Therapeutics Inc (CGEM) has a Forward P/S ratio of 95.66. This means the market is valuing CGEM at $95.66 for every dollar of expected revenue over the next 12 months.

CGEM Valuation